Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
35 stopped studies mapped to AML with Recurrent Genetic Abnormalities and descendants · 63% state a reason
Over the 35 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT07566585 | Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute… | Phase 1 | withdrawn | May 5, 2026 | BlueSphere Bio, Inc | Company Decision | Sponsor / business decision |
| NCT00540995 | Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem… | Phase 1 / Phase 2 | terminated | Oct 8, 2007 | City of Hope Medical Center | Unable to safely escalate to TMLI doses that were hypothesized to be effective and less toxic than… | Enrollment / accrual |
| NCT01028716 | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic… | Phase 2 | terminated | Dec 9, 2009 | Fred Hutchinson Cancer Center | The study experienced lower accrual rates after the onset of COVID. Upon review of the collected… | COVID-19 / pandemic |
| NCT00119366 | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and… | Phase 2 | terminated | Jul 13, 2005 | Fred Hutchinson Cancer Center | Funding ended before target accrual was reached; participants are no longer being examined or… | Enrollment / accrual |
| NCT01550185 | Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | terminated | Mar 9, 2012 | Roswell Park Cancer Institute | Sponsor wanted study rewritten | Other (stated, no rule matched) |
| NCT01876953 | Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid… | Phase 1 / Phase 2 | terminated | Jun 13, 2013 | City of Hope Medical Center | Due to the budget issues, the study discontinued at Phase II. | Funding |
| NCT02105116 | AML Therapy With Irradiated Allogeneic Cells | N/A | terminated | Apr 7, 2014 | Rutgers, The State University of New Jersey | No patients were eligible to receive the experimental component of the protocol therapy. | Other (stated, no rule matched) |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and… | Phase 2 | terminated | Jul 9, 2010 | City of Hope Medical Center | Low enrollment | Enrollment / accrual |
| NCT02030405 | Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Phase 2 | terminated | Jan 8, 2014 | Steven E. Coutre | Regulatory | Other (stated, no rule matched) |
| NCT01849276 | Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML | Phase 1 | terminated | May 8, 2013 | Northwestern University | Slow accrual | Enrollment / accrual |
| NCT01904643 | Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or… | Phase 1 | terminated | Jul 22, 2013 | Stanford University | Accrual factor | Enrollment / accrual |
| NCT00039091 | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer,… | Phase 1 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01548911 | Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia | Phase 2 | withdrawn | Mar 8, 2012 | Wake Forest University Health Sciences | not stated | Not stated |
| NCT01835288 | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Phase 2 | withdrawn | Apr 18, 2013 | Stanford University | not stated | Not stated |
| NCT01801046 | Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia | Phase 1 | terminated | Feb 28, 2013 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT01564277 | Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies | Phase 2 | terminated | Mar 27, 2012 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT02049801 | MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or… | Phase 1 | terminated | Jan 30, 2014 | Bruno C. Medeiros | logistics | Other (stated, no rule matched) |
| NCT01342887 | Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating… | Phase 1 / Phase 2 | terminated | Apr 27, 2011 | Fred Hutchinson Cancer Center | not stated | Not stated |
| NCT01076270 | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A… | N/A | terminated | Feb 26, 2010 | Fred Hutchinson Cancer Center | Funding withdrawal | Funding |
| NCT00673153 | Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated… | Phase 2 | terminated | May 7, 2008 | Fred Hutchinson Cancer Center | not stated | Not stated |
| NCT00863434 | Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal… | Phase 2 | terminated | Mar 18, 2009 | University of Washington | not stated | Not stated |
| NCT01465386 | Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission | Phase 2 | terminated | Nov 4, 2011 | Fred Hutchinson Cancer Center | Closed early due to slow enrollment | Enrollment / accrual |
| NCT01607645 | Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or… | Phase 2 | terminated | May 30, 2012 | Fred Hutchinson Cancer Center | The study was terminated early because there were other competing protocols. | Other (stated, no rule matched) |
| NCT00052598 | Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or… | Phase 1 / Phase 2 | terminated | Jan 27, 2003 | Fred Hutchinson Cancer Center | not stated | Not stated |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With… | Phase 2 | withdrawn | Jul 27, 2012 | University of Medicine and Dentistry of New Jersey | Funding unavailable | Funding |
| NCT02029417 | Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With… | Phase 2 | terminated | Jan 7, 2014 | Roswell Park Cancer Institute | Major revisions needed in study | Other (stated, no rule matched) |
| NCT01260714 | Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With… | Phase 1 | terminated | Dec 15, 2010 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT01521936 | Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive… | Phase 2 | terminated | Jan 31, 2012 | Roswell Park Cancer Institute | Lack of funding | Funding |
| NCT00387426 | Sunitinib in Treating Patients With Idiopathic Myelofibrosis | Phase 2 | terminated | Oct 13, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00049582 | Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | Phase 1 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00301769 | SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic… | Phase 1 | terminated | Mar 13, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01159301 | Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid… | Phase 1 | terminated | Jul 9, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00101231 | Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,… | Phase 1 | terminated | Jan 10, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00103272 | 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With… | Phase 1 | terminated | Feb 8, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01558778 | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem… | N/A | withdrawn | Mar 20, 2012 | Roswell Park Cancer Institute | device not available | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 20 days agoSource updated Sep 10, 2026source: clinicaltrials